NEW DELHI: Hyderabad-based Bharat Biotech’s pre-submission assembly was scheduled on June 23 for analysis of the World Health Organisation (WHO)’s Emergency Utilization Listing (EUL) of its native Covid-19 vaccine Covaxin.
Before, the past month, Bharat Biotech had advised it had filed 90 percent of the documentation required to get WHO’s EUL.
The remaining documents should be filed this month.
The External Affairs Ministry is coordinating with Bharat Biotech to procure WHO recognition for your own Covid-19 vaccine.
Covaxin is one of three vaccines presently being handled in India from the Covid-19 pandemic.
India began the world’s biggest vaccination push on January 16 this season in a pragmatic manner with health care workers (HCWs) getting inoculated first.
The Legislation of frontline employees (FLWs) began on February 2.
The following stage of Covid-19 vaccination originated from March 1 to people over 60 decades old and for individuals aged 45 and over with given co-morbid problems.
India started vaccination for many people aged over 45 in April 1.
Stage 3 of this vaccination drive was launched on May 1 to the inheritance belonging to this age group 18-44.
Bharat Biotech, WHO pre-submission Assembly on June 23: WHO
